ANDOVER, Mass., March 24, 2021 /PRNewswire/ -- TransMedics
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology
company that is transforming organ transplant therapy for patients
with end-stage lung, heart, and liver failure, announced today
the appointment of Stephanie Lovell
to its Board of Directors and as a member of the Nominating and
Corporate Governance Committee, effective March 22, 2021.
Ms. Lovell brings over 30 years of healthcare executive
management, legal and board experience in both the public and
private sectors. Ms. Lovell is the Executive Vice President,
Medicare and Chief Legal Officer for Blue Cross Blue Shield of
Massachusetts, the largest private
health plan in Massachusetts,
where she leads the company's Medicare business and government and
regulatory affairs functions. Prior to this role, Ms. Lovell was
Senior Vice President of Administration and General Counsel for
Boston Medical Center. Previously, she was First Assistant Attorney
General in the Office of the Attorney General for the Commonwealth
of Massachusetts. Ms. Lovell is
currently on the board of Cyclerion Therapeutics, Inc. (NASDAQ:
CYCN), and she serves on the boards of several non-profit
organizations. She holds a bachelor's degree from Hamilton College and a J.D. from Boston University School of Law.
"I am thrilled to welcome Stephanie to our board of directors.
Her experience is complementary to our current directors, and we
expect her insights to be instrumental in shaping our commercial
payors' strategy and furthering our commercial reach in the U.S.
transplant market," said Waleed
Hassanein, MD, President and Chief Executive Officer. "I am
looking forward to Stephanie's contributions as we continue to
advance transplant therapy and drive TransMedics' success."
"TransMedics is committed to improving people's lives through
its transformational work in organ transplantation," said Ms.
Lovell. "I look forward to working alongside my fellow
directors and company management to build upon this commitment and
TransMedics' position as a leading innovator in the transplant
About TransMedics Group, Inc.
TransMedics is the
world's leader in portable extracorporeal warm perfusion and
assessment of donor organs for transplantation. Headquartered in
Andover, Massachusetts, the
company was founded to address the unmet need for more and better
organs for transplantation and has developed technologies to
preserve organ quality, assess organ viability prior to transplant,
and potentially increase the utilization of donor organs for the
treatment of end-stage heart, lung, and liver failure.
This press release contains
forward looking statements relating to the future growth of
TransMedics and the potential of our technologies to increase the
utilization of donor organs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. These
risks and uncertainties include those identified under the heading
"Risk Factors" in our Annual Report on Form 10-K for the year ended
December 31, 2020, which is available
on the SEC's website at www.sec.gov. Additional information will be
made available by our annual and quarterly reports and other
filings that we make from time to time with the SEC. These
forward-looking statements speak only as of the date of this press
release. Factors or events that could cause our actual results to
differ may emerge from time to time, and it is not possible for us
to predict all of them. We undertake no obligation to update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
View original content to download
SOURCE TransMedics Group, Inc.